Селективная активация VDR – новаторский подход к профилактике и лечению вторичного гиперпаратиреоза, кардио- и ренопротекции


В.Ю. Шило

ФПДО ГОУ ВПО МГМСУ, Москва
Обсуждаются инновационные подходы к лечению вторичного гиперпаратиреоза при хронической болезни почек с помощью cелективных активаторов рецепторов витамина D.

:

Литература


1. Lucas R.C. One form of late rickets associated with albuminuria, rickets of adolescence. Lancet. 1883; 1: 993-994.
2. Fletcher H.M. Case of infantilism with polyuria and chronic renal disease. Proc. R. Soc. Med.1911; 4: 95.
3. Barber H. The bone deformities of renal dwarfism. Lancet. 1920; 1: 18-19.
4. Liu S.H., Su C, Chou S.K et al. Calcium and phosphorus metabolism in osteomalacia. V. The effect of varying levels and ratios of calcium to phosphorus intake on their serum levels, paths of excretion and balances, i the presence of continuous vitamin D therapy. J. Clin. Invest. 1937; 16: 603-616.
5. Liu S.H., Chu H.I. Studies on calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihydrotachysterol (AT10) and iron. Medicine (Balt). 1943; 22: 103-161.
6. Albright F. Drake T.G., Sulkovich H.W. Renal osteit fibrosa cystica. Bull. Johns. Hopkins Hosp. 1937; 60: 377-399.
7. Ellis H.A., Pierides A.M., Feest T.G. et al. Hystopathology of renal osteodystrophy with particular reference to the effect of I-hydroxyvitamin D3 in patients treated by long-term dialysis. Clin. Endocrinol. (Oxf.) 1977; 7(Suppl.): 31s-8.
8. Sherrard D.J., Hercz G., Pei Y. et al.The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int. 1993; 43(2): 436-442.
9. Ермоленко B.M., Родионова С.С., Павлова Е.А. и др. Патогенез и лечение патологии скелета у больных на заместительной почечной терапии. Нефрология и диализ. 2004; 6(2): 164-168.
10. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998 Nov; 32 (5 Suppl. 3): S112-119.
11. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004 Sep 23;351(13): 1296-1305.
12. Martola L., Barany P., Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of china? Blood Purif. 2005; 23(3): 203-210.
13. Гендлин Г.Е., Шило В.Ю., Томилина Н.А. и др. Гипертрофия миокарда левого желудочка и ее прогностическое значение при хронической болезни почек. Клиническая нефрология. 2009; 1: 22-28.
14. Braun J, Oldendorf M., Moshage W. et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am. J. Kidney Dis. 1996; 27(3): 394-401.
15. Mehrotra R, Adler S. Coronary artery calcification in nondialyzed patients with chronic kidney diseases. Am. J. Kidney Dis. 2005; 45(5): 963.
16. Hannan M.T., Felson D.T., Dawson-Hughes B. et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J. Bone Miner Res. 2000; 15(4): 710-720.
17. Drake T.A., Schadt E., Hannani K. et al. Genetic loci determining bone density in mice with diet-induced atherosclerosis. Physiol. Genomics. 2001; 5(4): 205-215.
18. Moe S., Drueke T., Cunningham J. et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-1953.
19. Ермоленко В.М. Фосфорно-кальциевый обмен и почки. В кн.: Нефрология. Руководство для врачей. Под ред. И. Е. Тареевой (ред.). М.: Медицина; 2000. С. 62-76.
20. Делмез М. Дж.А., Кайе М. Заболевания костной ткани. В кн.: Руководство по диализу. Ред. Дж. Даугирдас, П. Блейк, Т. Инг. 3 изд. Пер. с англ. под ред. А.Ю. Денисова и В.Ю. Шило. Тверь, Триада; 2003. С. 585-603.
21. Dusso A.S., Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 2011; 79(7): 715-729.
22. Goodman W.G., Quarles L.D. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008; 74(3): 276-88. Epub 2007Jun 13. Review.
23. Alem A.M., Sherrard D.J., Gillen D.L. et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58(1): 396-399.
24. Шило В.Ю., Денисов А.Ю. Ассоциированный с диализом бета-2-микроглобулиновый амилоидоз. Нефрология и диализ. 2003; 5(Прил. 1): 46-52.
25. Adragao T., Pires A., Lucas C. et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol. Dial. Transplant 2004; 19: 1480-1488.
26. Шило В.Ю., Гендлин Г.Е., Перекокин Ю.Н. и др. Кальциноз структур сердца у больных на программном гемодиализе: связь факторами риска и показателями внутрисердечной гемодинамики. Нефрология и диализ. 2003; 5 (1 Прил. 1): 58-67.
27. Yildiz I., Sagliker Y., Demirhan O. et al. International evaluation of unrecognizably uglifying human faces in late and severe secondary hyperparathyroidism in chronic kidney disease. Sagliker syndrome. A unique catastrophic entity, cytogenetic studies for chromosomal abnormalities, calcium-sensing receptor gene and GNAS1 mutations. Striking and promising missense mutations on the GNAS1 gene exons 1, 4, 10, 4. J. Ren. Nutr. 2012; 22(1): 157-161. Review.
28. Mazess R.B., Elangovan L. A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin. Nephrol. 2003; 59(5): 319-325.
29. Arenas M.D., Muray S., Amoedo M.L. et al. A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis. Nefrologia 2006; 26(2): 226-233.
30. Gu Y., Ding F., Chen N. et al. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study. Ren. Fail. 2005; 27(2): 205-212.
31. Шило В.Ю., Денисов А.Ю., Таубинский И.М. Кальцитриол в патогенетической терапии вторичного гиперпаратиреоза у больных на программном гемодиализе. Клиницист. 2007; 1: 53-63.
32. Brown A.J., Finch J., Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium andphosphate transport. J. Lab. Clin. Med. 2002; 139(5): 279-284.
33. Mizobuchi M., Finch J.L., Martin D.R. et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72(6): 709-715.
34. Martin K.J., Gonzalez M.G. et al. 19-Nor-1-a-25 Dihydroxyvitamin D2 (Paricalcitol) safety and affectively reduces the levels of the intact Parathyroid Hormone in patients on Hemodialysis. J. Am. Soc. Nephrol. 1998; 9: 1427-1432.
35. Lindberg J., Martin K. J. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56(4): 315-323.
36. Coyne D.W., Grieff M., Ahya S.N. et al Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am. J. Kidney Dis. 2002; 40(6): 1283-1288.
37. Sprague S.M., Liach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 64(4): 1483-1490.
38. Coyne D., Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 2006; 47(2): 263-276.
39. Teng M., Wolf M., Lowrie E. et al. Survival of patients undergoing hemodialysis with paricacitol or calcitriol therapy. N. Engl. J. Med. 2003; 349 (5): 446-456.
40. Marx S.E, Frye C., Khan S. et al. Comparative effectiveness of paricalcitol versus calcitriol treatment in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). National Kidney Foundation. Spring Clinical Meeting. April 14-16, 2010. Orlando, Florida. Abstract # 276.
41. Llach and M. Yudd. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 2001; 38(5): S45-S50.
42. Tonbul H.Z., Solak Y., Atalay H. et al. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren. Fail. 2012; 34(3): 297-303.
43. Block G.A., Martin K.J., de Francisco A.L. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004; 350: 1516-1525.
44. Block G.A., Zaun D., Smits G. et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a largecohort of hemodialysis patients. Kidney Int. 2010; 78: 578-589.
45. Block G.A., Zeig S., Sugihara J. et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2008; 23: 2311-2318.
46. Fishbane S., Shapiro W.B., Corry D.B. et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone:the ACHIEVE study results. Clin. J. Am. Soc. Nephrol. 2008; 3: 1718-1725.
47. Ketteler M., Martin K.J., Wolf M., et al. Paricalcitol versus cinacalcet plus low- dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol. Dial. Transplant. 2012 Mar 19. [Epub ahead of print].
48. Schumock G..T, Walton S.M., Lee T.A. et al. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron. Clin. Pract. 2011; 117(2): c 151-159.
49. Staniforth M.E., Cheng S.C., Coyne D.W. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 2005; 63(6): 454-60.
50. Hervas Sanchez J.G., Prados Garrido M.D., Polo Moyano A. et al. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. Nefrologia. 2011; 31(6): 697-706.
51. Kovesdy C.P., Lu J.L., Malakauskas S.M. et al. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am. J. Kidney Dis. 2012; 59(1): 58-66.
52. Cunningham J., Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int. 2011; 79(7): 702-707. Epub 2010 Oct 20. Review.
53. Li Y.C., Kong J., Wei M. et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002; 110: 229-238.
54. Zhou C., Lu F., Cao K. et al. Calcium-independent and 1,25(OH)2D3- dependent regulation of the renin-angiotensin system in Ialpha-hydroxylase knockout mice. Kidney Int. 2008; 74: 170-179.
55. Bodyak N., Ayus J.C., Achinger S. et al. Activated vitamin D attenuates leftventricular abnormalities induced by dietary sodium in Dahl salt-sensitiveanimals. Proc. Natl. Acad. Sci. USA 2007; 104: 16810-16815.
56. Simpson R.U., Hershey S.H., Nibbelink K.A. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem Mol. Biol. 2007; 103: 521-524.
57. Teng M., Wolf M., Ofsthun M.N. et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005; 16(4): 1115-1125.
58. Naves-Diaz M., Alvarez-Hernandez D., Passlick-Deetjen J. et al. Oral activevitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008; 74: 1070-1078.
59. Волков М., Смирнов А. Роль витамина D в кардио- и нефропротекции при хронической болезни почек. Врач. 2010; 7: 38-41.
60. Hirata M., Makibayashi K., Katsumata K. et al. Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 2002; 17(12): 2132-2137.
61. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-780.
62. Shinaberger C.S., Kopple J.D., Kovesdy C.P. et al. Ratio of paricalcitol dosageto serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1769-1776.
63. Schumock G.T., Arruda J.A.L., Marx S.E. et al. Economic comparison of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism impact of hospitalization and survival. J. Med. Econ. 2007; 10: 393-409.
64. Dobrez D.G., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitrioltreated patients in real-world clinical settings. Nephrol. Dial. Transplant. 2004; 19: 1174-1181.
65. Becker L.E., Koleganova N., Piecha G. et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am. J. Physiol. Renal. Physiol. 2011; 300(3): F772-82.
66. Thadhani R., Appelbaum E., Pritchett Y., et al. Vitamin D therapy and cardiac structure and function in patients with chroic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012; 307(7): 674-684.
67. Mizobuchi M., Morrissey J., Finch J.L. et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 2007; 18(6): 1796-1806.
68. Dusso A., Arcidiacono M.V., Yang J. et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J. Steroid. Biochem Mol. Biol. 2010; 121: 193-198.
69. Agarwal R., Acharya M., Tian J. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68(6): 2823-2828.
70. de Zeeuw D., Agarwal R., Amdahl M. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376(9752): 1543-51.F.


Об авторах / Для корреспонденции


Шило В.Ю. – медицинский директор Б. Браун Авитум Руссланд Клиникс, доцент кафедры нефрологии ФПДО ГОУ ВПО МГМСУ, к.м.н.
E-mail: nephrolog@gmail.com


Похожие статьи


Бионика Медиа